Federal abortion surveillance mandate buried in access-restriction bill
H.R. 1525 — Protecting Life from Chemical Abortions Act · Filed by Kevin Hern (R-OK) · 25 cosponsors · Introduced Feb 24, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill prohibits the federal government from declaring a public health emergency related to abortion and immediately terminates any such declaration currently in effect. It also reinstates the requirement that mifepristone (the abortion pill) be dispensed only in person at clinics, medical offices, or hospitals under a doctor's supervision—reversing the FDA's 2023 relaxation of that rule—and blocks the FDA from loosening these restrictions unless all states submit detailed abortion surveillance data to the CDC, including maternal demographics and abortion method.
Why we flagged it
The bill's operative mechanism is twofold: (1) it blocks federal emergency declarations on abortion and reinstates in-person dispensing rules for mifepristone, directly restricting access to medication abortion; (2) it conditions any future FDA regulatory flexibility on mandatory state abortion surveillance data collection, creating a de facto surveillance and access-restriction regime.
- Mandatory abortion surveillance data collection (Section 3(c)) with detailed demographic and clinical variables is substantively unrelated to the bill's stated purpose of prohibiting emergency declarations and reinstating dispensing rules. It functions as a separate regulatory control mechanism.
What the text implies
- The mandatory abortion surveillance system (Section 3(c)) creates a federal database of abortion procedures linked to maternal demographics, race, ethnicity, and marital status—data that could be subpoenaed, leaked, or weaponized against women and providers in states with abortion bans or criminal penalties.
- By conditioning any future FDA regulatory flexibility on complete state abortion data submission, the bill effectively gives states veto power over federal drug policy and creates pressure on states to criminalize or restrict abortion reporting to avoid triggering federal surveillance requirements.
The full analysis lists 4 implications of this text.
Who stands to gain
anti-abortion advocacy organizations; crisis pregnancy centers; pharmaceutical companies with competing contraceptive/fertility products